Get notified when LONA files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • We Will Not Receive Any Proceeds From the Sale of Our Common Stock By the Selling Stockholder. (new) — The offering is entirely secondary, so the company receives no capital from the share sales, only a nominal amount from warrant exercise.
NASDAQ: LONA LeonaBio, Inc. 424B3

LeonaBio files for secondary offering of up to 5.5M shares by selling stockholder; company gets only ~$5,502

Filed April 2, 2026 · ~1 min read

Key Changes

  • high

    This is a secondary offering: selling stockholder Sermonix may sell up to 5,502,402 shares; LeonaBio receives no proceeds from those sales.

    The Offering verify on EDGAR →
  • high

    The only cash to LeonaBio is up to ~$5,502 from cash exercise of a pre-funded warrant at $0.001/share, to be used for working capital and pipeline.

    Use of Proceeds verify on EDGAR →
  • medium

    The warrant was issued as partial consideration for a license agreement with Sermonix for lasofoxifene; full terms not detailed in this prospectus.

    Prospectus Summary verify on EDGAR →

1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (MU 10-K) is open in full — no account needed.

Partner

Trade LONA commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 3, 2026 · How we verify